At-Home Biosensing Platform Developer Gets $27M Investment

SiPhox Health, an MIT spinout developing laboratory-grade home health testing using silicon photonics technology, has secured $27 million in financing — $10 million in seed financing and $17 million in a series A round.

According to SiPhox, the series A funding will enable team expansion as the company works to achieve FDA clearance for its SiPhox Home platform. The company said it plans for the solution to offer users a menu of proteins and hormone tests from a finger prick blood sample, and to deliver results in five minutes or less. SiPhox Health has launched a mail-in blood collection kit that measures 17 biomarkers for inflammation and metabolic, hormonal, and cardiovascular health.

SiPhox Health co-founders: CEO Diedrik Vermeulen (right) is holding a 12-in. silicon photonics wafer with SiPhox's sensor chips. Chief product officer Michael Dubrovsky is holding the SiPhox Home device. Courtesy of Business Wire.

SiPhox Health co-founder and chief product officer Michael Dubrovsky said that the company sees its technology eventually enabling a wearable device that measures proteins, hormones, and small molecules, continuously.

Intel Capital led the investment, and Intel Capital managing director Srini Ananth will join SiPhox Health’s board of directors.